Allergy, Volume 78, Issue 12, Page 3043-3045, December 2023 ..read more

Allergy, EarlyView ..read more

Sphingolipid metabolism in childhood asthma. Abstract Background While dysregulated sphingolipid metabolism has been associated with risk of childhood asthma, the specific sphingolipid classes and/or mechanisms driving this relationship remain unclear. We aimed to understand the multifaceted role between sphingolipids and other established asthma risk factors that complicate this relationship. Methods We performed targeted LC–MS/MS-based quantification of 77 sphingolipids in plasma from 997 children aged 6 years from two independent cohorts (VDAART and COPSAC2010). We examined associations o ..read more

Abstract Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well-known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%–3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence-based recommendations for the diagnosis and management o ..read more

This study evaluates the safety, tolerability, and immunogenicity of a peanut vaccine, ASP0892, after intradermal or intramuscular injection in adults and adolescents with peanut allergy in two phase 1 clinical studies. Both studies of ASP0892 (ARA-LAMP-Vax) vaccine showed no significant safety issues and modest but non-relevant modifications in clinical or immune responses in adults or adolescents with peanut allergy. The safety and immunogenicity potential of ASP0892 may warrant future explorations of LAMP-Vax vaccines for immunotherapeutic treatment of other diseases. Ara h, Arachis hypoga ..read more

Allergy, EarlyView ..read more

After 2 years of donidalorsen treatment in this phase 2 OLE study, injection site discoloration and reaction were the only treatment-related adverse events reported in >1 patient. Donidalorsen treatment resulted in a sustained mean 96.0% reduction from baseline in HAE attack rates, with a mean ≈1 attack/year (median 0.04). 100.0% of patients treated with donidalorsen had clinically significant improvements in quality-of-life at week 105. Abstract Background Hereditary angioedema (HAE) is a potentially fatal disease characterized by unpredictable, recurrent, often disabling swelling attack ..read more

In this pool of patients with moderate-to-severe AD, 53% reported at least one allergic comorbidity (asthma, conjunctivitis, rhinitis, or food allergies). Abrocitinib 200 mg or 100 mg monotherapy improved clinical, patient-reported, and HRQoL outcomes versus placebo, regardless of patients' allergic comorbidities. In patients with moderate-to-severe AD, abrocitinib is efficacious and well tolerated in those with or without allergic comorbidities. Abstract Background Abrocitinib efficacy by comorbidity status in patients with moderate-to-severe atopic dermatitis (AD) has not been previously a ..read more

Allergy, EarlyView ..read more

Allergy, EarlyView ..read more